Clinical application of next-generation sequencing in early screening of neonatal diseases.
10.7499/j.issn.1008-8830.2409107
- Author:
Li-Hong JIANG
1
;
Ben-Qing WU
1
;
Zheng-Yan ZHAO
Author Information
1. Department of Pediatrics, Shenzhen Guangming District People's Hospital, Shenzhen, Guangdong 518000, China.
- Publication Type:Journal Article
- Keywords:
Genetic screening;
Inherited metabolic disorder;
Neonatal screening;
Neonate;
Tandem mass spectrometry
- MeSH:
Humans;
Infant, Newborn;
High-Throughput Nucleotide Sequencing/methods*;
Neonatal Screening/methods*;
Tandem Mass Spectrometry;
Prospective Studies;
Female;
Male;
Infant, Newborn, Diseases/diagnosis*;
Genetic Testing
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(4):432-437
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To evaluate the clinical value of next-generation sequencing (NGS) in neonatal disease screening, particularly its advantages when combined with tandem mass spectrometry (MS/MS).
METHODS:A prospective study was conducted involving blood samples from 1 999 neonates born at the Shenzhen Guangming District People's Hospital, between May and August 2021. All samples were initially screened using MS/MS and fluorescence immunoassay, followed by NGS to detect high-frequency variation sites in 135 related pathogenic genes. Suspected positive variants were validated using Sanger sequencing or multiplex ligation-dependent probe amplification in family studies.
RESULTS:No confirmed positive cases were found in the MS/MS analysis of the 1 999 neonates. Genetic screening identified 58 positive cases (2.90%), 732 carriers of pathogenic genes (36.62%), and 1 209 negative cases (60.48%). One case of neonatal intrahepatic cholestasis was diagnosed (0.05%, 1/1 999). Fluorescence immunoassay identified 39 cases of glucose-6-phosphate dehydrogenase (G6PD) deficiency (1.95%, 39/1 999), while genetic screening identified 43 cases of G6PD deficiency (2.15%, 43/1 999). The fluorescence immunoassay also detected 6 cases of hyperthyrotropinemia (0.30%, 6/1 999), all of whom carried DUOX2 gene variants. The top ten pathogenic gene carrier rates were G6PD (12.8%), DUOX2 (8.7%), HBB (8.2%), ATP7B (6.6%), GJB2 (5.7%), SLC26A4 (5.6%), PAH (5.6%), ACADSB (4.6%), SLC25A13 (4.2%), and SLC22A5 (4.1%).
CONCLUSIONS:NGS can serve as an effective complement to MS/MS, significantly improving the detection rate of inherited metabolic disorders in neonates. When combined with family validation, it enables precise diagnosis, particularly demonstrating complementary advantages in screening for monogenic diseases such as G6PD deficiency.
